http://www.eurekalert.org/pub_releases/2012-06/gh-psa060712.php
Merck announced results of a post-hoc pooled analysis in which patients with type 2 diabetes age 65 or older treated with JANUVIA® (sitagliptin) 100 mg/day achieved similar blood sugar reductions as those treated with a sulfonylurea, with significantly less hypoglycemia (low blood sugar).
Merck announced results of a post-hoc pooled analysis in which patients with type 2 diabetes age 65 or older treated with JANUVIA® (sitagliptin) 100 mg/day achieved similar blood sugar reductions as those treated with a sulfonylurea, with significantly less hypoglycemia (low blood sugar).